Damora Therapeutics, Inc. (DMRA)
NASDAQ (NMS) NASDAQ (CM) Primary NASDAQ (NMS) Summary
DMRA Chart
What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
Does Galecto, Inc. (DMRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Galecto (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Damora Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 40 | $1,036 | $1,354.8 | $318.8 | 30.77% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.19M | $30.6M | $39.38M | $8.78M | 28.69% |
 Rekah Franca Catalyst Funds Management Pty Ltd. | 17,293 | $447,889 | $591,247.67 | $143,358.67 | 32.01% |
| KJ Ken Joseph Braidwel LLP | 894,846 | $23.18M | $29.91M | $6.73M | 29.06% |
 Ilko Menkov Vestal Point Capita LLP | 600,000 | $15.54M | $20.3M | $4.76M | 30.62% |
Damora Therapeutics, Inc. (DMRA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Damora Therapeutics, Inc. ever had a stock split?
Damora Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Lori C. Firmani CEO | NASDAQ (NMS) Exchange | 36322Q206 CUSIP |
| US Country | 5 Employees | - Last Dividend | 30 Aug 2024 Last Split | - IPO Date |
Overview
Galecto, Inc. is a clinical-stage biotechnology company dedicated to the development of novel molecules for treating a broad spectrum of diseases, including fibrosis, cancer, inflammation, and other related conditions. Established in 2011 and based in Copenhagen, Denmark, the company has quickly become a notable entity in the biotech sector, focusing on leveraging its expertise in galectin and LOXL2 inhibitors to advance potential treatments for diseases that currently have limited therapeutic options.
Products and Services
- GB2064
GB2064 stands as Galecto, Inc.'s lead product candidate, currently undergoing a Phase IIa clinical trial for the treatment of myelofibrosis, a rare type of bone marrow cancer that disrupts the body’s normal production of blood cells. GB2064 is characterized as a selective oral small molecule inhibitor of LOXL2 (lysyl oxidase-like 2), which plays a significant role in the crosslinking of collagen and elastin, contributing to the fibrosis in various organs. By inhibiting LOXL2, GB2064 aims to reduce or halt the progression of fibrotic diseases, offering a novel therapeutic pathway for conditions currently lacking effective treatments.
- GB1211
GB1211 is another prominent component of Galecto, Inc.'s pipeline, acting as a selective oral galectin-3 inhibitor. Galectin-3 is a protein involved in numerous biological processes, including fibrosis, inflammation, and cancer progression. By inhibiting this protein, GB1211 is being investigated as a potential treatment for cancer and fibrosis. Its development currently encompasses both a Phase IIa trial targeting cancer treatments and a Phase Ib/IIa trial aimed at addressing fibrosis. The dual application of GB1211 highlights Galecto, Inc.'s strategic approach to targeting multifaceted pathways involved in serious health conditions.
